The KIRIN HEALTH INNOVATION FUND Invests in… Leave a comment

<![CDATA[ function CopyToClipboard(text, type) { if (!navigator.clipboard) { return; } navigator.clipboard.writeText(text).then(function() { console.log('Copying to clipboard was successful!'); }, function(err) { console.error('Could not copy text: ', err); }); alert("COPY/PASTE: This link is designed for copying the relevant security "+type+". You can now paste it to your liking."); return false; } function showDiscover_pdf() { var myDivPubBg = document.getElementById('dPubBg'); var myDivPubInter = document.getElementById('dPubInter'); var myDivPubContent = document.getElementById('dPubBgC'); var myDivPubContent2 = document.getElementById('dPubBgC2_pdf'); var myTabPP = document.getElementById('tabpopup'); var AvH = window.innerHeight – 650; if (window.innerHeight<650) AvH=window.innerHeight; if (AvH<0) AvH=0; myDivPubContent.innerHTML = myDivPubContent2.innerHTML; document.getElementById('divpopup').innerHTML = "”; = ‘-420px’; myTabPP.width = “700px”; = ‘100%’; = ‘100%’; = ‘#6b6b6b’;’block’; = (AvH/2)+’px’;’block’; document.getElementById(“divpopup”).style.display = “block”; } function closeDiscover_pdf() { var myDivPubBg = document.getElementById(‘dPubBg’); var myDivPubInter = document.getElementById(‘dPubInter’); var myDivPubContent = document.getElementById(‘dPubBgC’); var myDivPubContent2 = document.getElementById(‘dPubBgC2_pdf’); myDivPubContent.innerHTML = myDivPubContent2.innerHTML; = ‘-400px’; = ‘0%’; = ‘0%’;’none’;’none’; = “none”; document.getElementById(‘divpopup’).style.display = “none”; document.getElementById(‘divpopup’).innerHTML = “”; } ]]> fermer

Delayed Japan Exchange  –  02:00 2022-08-25 am EDT
2267.00 JPY   +0.35%

{SS_ISE_LOADED.push(event);}) ]]>

‘); $(‘#TABLEARTICLE’).find(‘tr:gt(10)’).hide(); $(‘#TABLEARTICLE’).find(‘tr:nth-child(11)’).click(function() { $(this).remove(); $(‘#TABLEARTICLE’).find(‘tr’).show(); }); } } }); <![CDATA[ $(function() { var sHTMLGraphCours = "“; if(window.screen.width0) { if(window.screen.width0) { if(window.screen.width0) { if(window.screen.width0) { if(window.screen.width0) { if(window.screen.width0) { if(window.screen.width0) { if(window.screen.width0) { if(window.screen.width0) { if(window.screen.width0) { if(window.screen.width

<![CDATA[ var sHTMLAutopromo = "
The best opportunities. All the markets. Each month. In one click. Discover &nbsp “; $(function(){ $.each($(“.autopromo”),function(index,elmnt){ $(elmnt).css(“display”,””); $(elmnt).html(sHTMLAutopromo); }); if(window.screen.width

TOKYO – The KIRIN HEALTH INNOVATION FUND, a corporate venture capital (CVC)*?fund founded by Kirin Holdings Company, Limited (Kirin Holdings) and Global Brain Corporation, a leading independent venture capital firm, has invested in WRAY, Inc.(WRAY).

1: The practice of an operating company investing its corporate funds directly in an external startup company aligned with its business lines, intended to establish a mutually beneficial relationship or launch a new business by leveraging the latter’s assets.

WRAY’s vision and mission is to address the wellness of women, who are vulnerable to the effects of hormonal imbalance at various stages of their lives, and to create a world in which women can achieve their true potential. The WRAY brand has established a unique position in the women’s healthcare market in Japan as a wellness brand that is close to women, providing information that helps working women focus on their own health and developing products and services that enable easy self-care. Through this investment, Kirin Holdings will explore initiatives to solve women’s health issues together with WRAY, while leveraging the Kirin Group’s knowledge of health science.

About WRAY, Inc.

WRAY is a start-up company that focuses on the effects of hormonal balance and menstrual cycles on women’s health care, and is developing a variety of self-care products and a menstrual cycle tracking service on line under the brand name ‘WRAY’. WRAY develops and sells beauty care products, health foods, apparel, delicate-zone soaps, and other products that address women’s concerns that may not be readily apparent. WRAY has earned the trust of working women in their 20s to 40s by its brand appeal as a ‘wellness brand that caters to women’ and its unique product development capabilities that no other company has. In addition to expanding its product lineup, WRAY plans to launch an online community and offer a wide range of wellness programs.

Purpose of Establishing the KIRIN HEALTH INNOVATION FUND

Through the KIRIN HEALTH INNOVATION FUND, Kirin Holdings intends to invest in startups around the globe that have innovative technologies and business models for resolving health issues, and to leverage their advanced health science technologies and solutions for improving customer experience. By combining the Kirin Group’s wealth of assets and competence in health science with innovations and technologies that startups will bring to partnerships, Kirin Holdings will be better able to bolster its existing Food & Beverages domain as well as step up efforts to launch new businesses in its Health Science domain.

About Kirin Holdings

Kirin Holdings Company, Limited is an international company that operates in the Food & Beverages domain (Food & Beverages businesses), Pharmaceuticals domain (Pharmaceuticals businesses), and Health Science domain (Health Science business), both in Japan and across the globe.

Kirin Holdings can trace its roots to Japan Brewery which was established in 1885. Japan Brewery became Kirin Brewery in 1907. Since then, the company expanded its business with fermentation and biotechnology as its core technologies, and entered the pharmaceutical business in the 1980s, all of which continue to be global growth centers. In 2007, Kirin Holdings was established as a pure holding company and is currently focusing on boosting its Health Science domain.

Under the Kirin Group Vision 2027 (KV 2027), a long-term management plan launched in 2019, the Kirin Group aims to become ‘A global leader in CSV*, creating value across our world of Food & Beverages to Pharmaceuticals.’ Going forward, the Kirin Group will continue to leverage its strengths to create both social and economic value through its businesses, with the aim of achieving sustainable growth in corporate value.

Creating Shared Value: combined added value for consumers as well as for society at large.


Tel: 81-3-6837-7028

(C) 2022 Electronic News Publishing, source ENP Newswire

<![CDATA[ $('#TABLEARTICLE').on('mouseover.tabBodyLV17','.LChartI', function(event) { var this_ = this; var width = 300; var codezb = $(this_).parent().find("a").attr("codezb");/*$("div.iconeSuppr", $(this_).closest("tr")).attr("codezb");*/ var at = $(this_).parent().find("a").attr("at"); var elemRect = this.getBoundingClientRect(),/*+ window.scrollY,*/ siteRect = $("#myCENTER")[0].getBoundingClientRect(), x_offset = elemRect.left – siteRect.left + 35; var img = "“; var LChart = $(‘#LChart’); LChart.detach() .insertAfter(this) .css(“left”, x_offset) .html(img).css(“display”, “block”); $(this_).on(‘mouseout’, function() { $(‘#LChart’).css(“display”, “none”); $(this_).off( “mouseout”); }); }); ]]> 10) { $(‘#TABLEARTICLE’).find(‘tr:nth-child(10)’).after(‘

More Results]]>


Analyst Recommendations on KIRIN HOLDINGS COMPANY, LIMITED

Sales 2022 1 941 B 14 181 M 14 181 M
Net income 2022 122 B 893 M 893 M
Net Debt 2022 356 B 2 598 M 2 598 M
P/E ratio 2022 14,9x
Yield 2022 2,94%
Capitalization 1 843 B 13 467 M 13 467 M
EV / Sales 2022 1,13x
EV / Sales 2023 1,11x
Nbr of Employees 29 515
Free-Float 87,5%

Duration : Auto.2 months3 months6 months9 months1 year2 years5 years10 yearsMax. Period : DayWeek

Kirin Holdings Company, Limited Technical Analysis Chart | MarketScreener

Technical analysis trends KIRIN HOLDINGS COMPANY, LIMITED

Short Term Mid-Term Long Term
Trends Bullish Bullish Bullish

Income Statement Evolution

Please enable JavaScript in your browser’s settings to use dynamic charts.



Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 2 259,00 JPY
Average target price 2 399,33 JPY
Spread / Average Target 6,21%

Please enable JavaScript in your browser’s settings to use dynamic charts.


Leave a Reply